Compare Amer Sports Inc (AS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amer Sports Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Amer Sports Inc trades at $33.87 (market cap $21.04B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.3× Amer Sports Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Amer Sports Inc nearer its low. Which is the better fit depends on your goals.
| AS | VRTX | |
|---|---|---|
Market Cap | $21.04B | $132.79B |
Sector | Technology | Health |
52-Week High | $41.96 | $529.59 |
52-Week Low | $29.54 | $374.46 |
Enterprise Value | $21.36B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amer Sports (AS) trades at $36.84, up 2.02% today, with a bullish technical signal from moving averages and strong analyst consensus. The company reported robust Q1 2026 results, beating EPS estimates with $0.38 versus $0.31 expected, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion, driven by strength in Arc'teryx and Salomon brands.
Outlook is positive given earnings momentum and raised 2026 guidance, but risks include high valuation (P/E 45.2) and dependence on premium brand sustainability. The consensus price target of $58.67 implies significant upside, supported by 12 buy ratings. Investors should monitor Q2 2026 earnings on August 18 for continued growth validation.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
